electroCore, Inc.
NASDAQ:ECOR
Intrinsic Value
electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. [ Read More ]
The intrinsic value of one ECOR stock under the Base Case scenario is 16.54 USD. Compared to the current market price of 5.65 USD, electroCore, Inc. is Undervalued by 66%.
Valuation Backtest
electroCore, Inc.
Run backtest to discover the historical profit from buying and selling ECOR stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
electroCore, Inc.
Current Assets | 14.3m |
Cash & Short-Term Investments | 10.3m |
Receivables | 717k |
Other Current Assets | 3.2m |
Non-Current Assets | 1.8m |
PP&E | 706k |
Other Non-Current Assets | 1.1m |
Current Liabilities | 8.1m |
Accounts Payable | 2.2m |
Accrued Liabilities | 5.4m |
Other Current Liabilities | 517k |
Non-Current Liabilities | 537k |
Other Non-Current Liabilities | 537k |
Earnings Waterfall
electroCore, Inc.
Revenue
|
16m
USD
|
Cost of Revenue
|
-2.8m
USD
|
Gross Profit
|
13.2m
USD
|
Operating Expenses
|
-32.5m
USD
|
Operating Income
|
-19.3m
USD
|
Other Expenses
|
435k
USD
|
Net Income
|
-18.8m
USD
|
Free Cash Flow Analysis
electroCore, Inc.
What is Free Cash Flow?
ECOR Profitability Score
Profitability Due Diligence
electroCore, Inc.'s profitability score is 30/100. The higher the profitability score, the more profitable the company is.
Score
electroCore, Inc.'s profitability score is 30/100. The higher the profitability score, the more profitable the company is.
ECOR Solvency Score
Solvency Due Diligence
electroCore, Inc.'s solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Score
electroCore, Inc.'s solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ECOR Price Targets Summary
electroCore, Inc.
According to Wall Street analysts, the average 1-year price target for ECOR is 23.56 USD with a low forecast of 15.15 USD and a high forecast of 31.5 USD.
Ownership
ECOR Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ECOR Price
electroCore, Inc.
Average Annual Return | -46.97% |
Standard Deviation of Annual Returns | 36.15% |
Max Drawdown | -97% |
Market Capitalization | 33.9m USD |
Shares Outstanding | 6 002 630 |
Percentage of Shares Shorted | 0.18% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
electroCore, Inc. engages in the provision of non-invasive vagus nerve stimulation (nVNS) therapy. The company is headquartered in Rockaway, New Jersey and currently employs 52 full-time employees. The company went IPO on 2018-06-22. nVNS is a platform for bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The firm is providing gammaCore device for the treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults. gammaCore permits patients to self-administer doses of nVNS on an as-needed basis for treatment of prevent multiple types of headache pain via the vagus nerve. The gammaCore therapy is also used to treat primary headache, including migraine, cluster headache (CH), hemicrania continua and paroxysmal hemicrania (PH) and coronavirus (COVID-19).
Contact
IPO
Employees
Officers
The intrinsic value of one ECOR stock under the Base Case scenario is 16.54 USD.
Compared to the current market price of 5.65 USD, electroCore, Inc. is Undervalued by 66%.